These big medtech names performed the best in early 2017

Boston Scientific

[Image courtesy of Boston Scientific]

Boston Scientific: 15%

Boston Scientific has had a busy 1st quarter, investing $45 million in robotic platform maker Corindus Vascular Robotics, putting up $435 million for replacement heart valve developer Symetis and reportedly eyeing a buyout of mitral valve maker Neovasc.
The Marlborough, Mass.–based company has seen share value grow roughly 15% so far in the year, beginning the year at $21.63 and hitting $24.87 on March 31.
The solid share performance comes despite stock values dipping nearly 5% in February after the company announced a voluntary recall of its Lotus transcatheter aortic valve replacement over issues with its locking mechanism.
The company said it reportedly found a “fix” for issues with its Lotus Edge heart valve in January, and is hopeful to file for premarket approval with the FDA some time in May.
Want to stay on top of MDO content? Subscribe to our e-newsletter.

Pages: 1 2 3 4 5 6 7 8

Speak Your Mind